DrugPatentWatch Database Preview

Details for Patent: 6,074,670

« Back to Dashboard

Which drugs does patent 6,074,670 protect, and when does it expire?

Patent 6,074,670 protects TRICOR and is included in one NDA.

This patent has eighty-five patent family members in thirty-six countries.

Summary for Patent: 6,074,670

Title:	Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
Abstract:	The invention provides an immediate-release fenofibrate composition comprising (a) an inert hydrosoluble carrier covered with at least one layer containing fenofibrate in a micronized form having a size less than 20 .mu.m, a hydrophilic polymer and, optionally, a surfactant, the polymer making up at least 20% by weight of (a); and (b) optionally one or several outer phase(s) or layers(s). The invention also provides a method for preparing said composition.
Inventor(s):	Stamm; Andre (Griesheim, FR), Seth; Pawan (Irvine, CA)
Assignee:	Laboratoires Fournier, S.A. (Dijon, FR)
Application Number:	09/005,128
Patent Claim Types: see list of patent claims	Composition; Formulation; Dosage form; Process;

Drugs Protected by US Patent 6,074,670

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Abbvie Inc	TRICOR	fenofibrate	TABLET;ORAL	021203-001	Sep 4, 2001		DISCN	Yes	No
Abbvie Inc	TRICOR	fenofibrate	TABLET;ORAL	021203-003	Sep 4, 2001		DISCN	Yes	No

Foreign Priority and PCT Information for Patent: 6,074,670

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	97 00479	Jan 17, 1997

Non-Orange Book US Patents Family Members for Patent 6,074,670

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,329,214	Process for producing fenofibrate tablets
6,596,317	Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
6,652,881	Fenofibrate pharmaceutical composition having high bioavailability
6,277,405	Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it

International Patents Family Members for US Patent 6,074,670

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Ukraine	61096
Turkey	9901660
Tunisia	SN98009
Slovakia	285847